Zhitong Finance App News, Forson Pharmaceutical (01652.HK) announced that in China's 12th batch of centralized drug procurement tenders on July 31, 2026, the company's four products are to win the bid: nicardipine injection (2ml: 2mg, 5ml: 5mg), mesartan potassium tablets (40mg, 80mg), and compound potassium hydrogen phosphate injection (5ml: 1.12g of potassium dihydrogen phosphate and dipotassium hydrogen phosphate (based on K2HPO4) 1.18g) and dipotassium hydrogen phosphate (10mg tablets).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.